Your browser doesn't support javascript.
loading
Geriatric nutritional risk index as an easy-to-use assessment tool for nutritional status in hepatocellular carcinoma treated with atezolizumab plus bevacizumab.
Hiraoka, Atsushi; Kumada, Takashi; Tada, Toshifumi; Hirooka, Masashi; Kariyama, Kazuya; Tani, Joji; Atsukawa, Masanori; Takaguchi, Koichi; Itobayashi, Ei; Fukunishi, Shinya; Tsuji, Kunihiko; Ishikawa, Toru; Tajiri, Kazuto; Ochi, Hironori; Yasuda, Satoshi; Toyoda, Hidenori; Ogawa, Chikara; Nishimura, Takashi; Hatanaka, Takeshi; Kakizaki, Satoru; Shimada, Noritomo; Kawata, Kazuhito; Naganuma, Atsushi; Kosaka, Hisashi; Matono, Tomomitsu; Kuroda, Hidekatsu; Yata, Yutaka; Ohama, Hideko; Tada, Fujimasa; Nouso, Kazuhiro; Morishita, Asahiro; Tsutsui, Akemi; Nagano, Takuya; Itokawa, Norio; Okubo, Tomomi; Arai, Taeang; Imai, Michitaka; Koizumi, Yohei; Nakamura, Shinichiro; Iijima, Hiroko; Kaibori, Masaki; Hiasa, Yoichi.
Afiliação
  • Hiraoka A; Gastroenterology Center, Ehime Prefectural Central Hospital, Matsuyama, Japan.
  • Kumada T; Department of Nursing, Gifu Kyoritsu University, Ogaki, Japan.
  • Tada T; Department of Internal Medicine, Japanese Red Cross Himeji Hospital, Himeji, Japan.
  • Hirooka M; Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Toon, Japan.
  • Kariyama K; Department of Hepatology, Okayama City Hospital, Okayama, Japan.
  • Tani J; Department of Gastroenterology and Hepatology, Kagawa University, Takamatsu, Kagawa, Japan.
  • Atsukawa M; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan.
  • Takaguchi K; Department of Hepatology, Kagawa Prefectural Central Hospital, Takamatsu, Japan.
  • Itobayashi E; Department of Gastroenterology, Asahi General Hospital, Asahi, Japan.
  • Fukunishi S; Department of Gastroenterology, Osaka Medical and Pharmaceutical University, Osaka, Japan.
  • Tsuji K; Center of Gastroenterology, Teine Keijinkai Hospital, Sapporo, Japan.
  • Ishikawa T; Department of Gastroenterology, Saiseikai Niigata Hospital, Niigata, Japan.
  • Tajiri K; Department of Gastroenterology, Toyama University Hospital, Toyama, Japan.
  • Ochi H; Hepato-biliary Center, Japanese Red Cross Matsuyama Hospital, Matsuyama, Japan.
  • Yasuda S; Department of Gastroenterology and Hepatology, Ogaki Municipal Hospital, Ogaki, Japan.
  • Toyoda H; Department of Gastroenterology and Hepatology, Ogaki Municipal Hospital, Ogaki, Japan.
  • Ogawa C; Department of Gastroenterology, Japanese Red Cross Takamatsu Hospital, Takamatsu, Japan.
  • Nishimura T; Department of Gastroenterology and Hepatology, Hyogo College of Medicine, Nishinomiya, Japan.
  • Hatanaka T; Department of Gastroenterology, Gunma Saiseikai Maebashi Hospital, Maebashi, Gunma, Japan.
  • Kakizaki S; Department of Clinical Research, National Hospital Organization Takasaki General Medical Center, Takasaki, Japan.
  • Shimada N; Division of Gastroenterology and Hepatology, Otakanomori Hospital, Kashiwa, Japan.
  • Kawata K; Hepatology Division, Department of Internal Medicine II, Hamamatsu University School of Medicine, Hamamatsu, Japan.
  • Naganuma A; Department of Gastroenterology, National Hospital Organization Takasaki General Medical Center, Takasaki, Japan.
  • Kosaka H; Department of Surgery, Kansai Medical University, Hirakata, Japan.
  • Matono T; Department of Hepatology, St. Mary's Hospital, Himeji, Japan.
  • Kuroda H; Division of Hepatology, Department of Internal Medicine, Iwate Medical University, School of Medicine, Morioka, Japan.
  • Yata Y; Department of Gastroenterology, Hanwa Memorial Hospital, Osaka, Japan.
  • Ohama H; Gastroenterology Center, Ehime Prefectural Central Hospital, Matsuyama, Japan.
  • Tada F; Gastroenterology Center, Ehime Prefectural Central Hospital, Matsuyama, Japan.
  • Nouso K; Department of Hepatology, Okayama City Hospital, Okayama, Japan.
  • Morishita A; Department of Gastroenterology and Hepatology, Kagawa University, Takamatsu, Kagawa, Japan.
  • Tsutsui A; Department of Hepatology, Kagawa Prefectural Central Hospital, Takamatsu, Japan.
  • Nagano T; Department of Hepatology, Kagawa Prefectural Central Hospital, Takamatsu, Japan.
  • Itokawa N; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan.
  • Okubo T; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan.
  • Arai T; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan.
  • Imai M; Department of Gastroenterology, Saiseikai Niigata Hospital, Niigata, Japan.
  • Koizumi Y; Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Toon, Japan.
  • Nakamura S; Department of Internal Medicine, Japanese Red Cross Himeji Hospital, Himeji, Japan.
  • Iijima H; Department of Gastroenterology and Hepatology, Hyogo College of Medicine, Nishinomiya, Japan.
  • Kaibori M; Department of Surgery, Kansai Medical University, Hirakata, Japan.
  • Hiasa Y; Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Toon, Japan.
Hepatol Res ; 53(10): 1031-1042, 2023 Oct.
Article em En | MEDLINE | ID: mdl-37306040
ABSTRACT

AIM:

The present study focused on Geriatric Nutritional Risk Index (GNRI), which is based on bodyweight and serum albumin, and known as an easy-to-use nutritional assessment tool in clinical settings, to elucidate the prognostic predictive ability of GNRI in patients treated with atezolizumab plus bevacizumab (Atez/Bev) for hepatocellular carcinoma (HCC).

METHODS:

A total of 525 HCC patients treated with Atez/Bev, based on their classification of unsuitable status for curative treatments and/or transarterial catheter chemoembolization, were enrolled (Child-Pugh ABC = 484401, Barcelona Clinic Liver Cancer stage 0ABCD = 72519228318). Prognosis was evaluated retrospectively using GNRI.

RESULTS:

Atez/Bev was used in 338 of the present cohort as first-line systemic chemotherapy (64.4%). Median progression-free survival based on GNRI indicating normal, mild decline, moderate decline, and severe decline was 8.3, 6.7, 5.3, and 2.4 months, respectively, whereas median overall survival was 21.4, 17.0, 11.5. and 7.3 months, respectively (both p < 0.001). The concordance index (c-index) values of GNRI for predicting prognosis (progression-free survival/overall survival) were superior to those of Child-Pugh class and albumin-bilirubin grade (0.574/0.632 vs. 0.527/0.570 vs. 0.565/0.629). As a subanalysis, muscle volume loss was observed in 37.5% of 256 patients with computed tomography data available. Along with GNRI decline, frequency of muscle volume loss became progressively larger (normal vs. mild vs. moderate vs. severe = 17.6% vs. 29.2% vs. 41.2% vs. 57.9%, p < 0.001), and a GNRI value of 97.8 was predictive of its occurrence (AUC 0.715, 95% CI 0.649-0.781; specificity/sensitivity = 0.644/0.688).

CONCLUSION:

These findings indicate that GNRI is an effective nutritional prognostic tool for predicting prognosis and muscle volume loss complication in HCC patients treated with Atez/Bev.
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article